[Nettime-bold] Barrons article on DNAP- Clinics for the Future !!

[Listmember45@aba.com]

Title: Dnaprint

Text version below:

 Dnaprint (DNAP) is an emerging biotech company in this weeks Barrons.

1) CEO (Dr. Tony Frudakis) Lead scientist for Corixa starts his own company a few months ago

2) Company is formed by a reverse merger of a pinksheet company

3) DNAP has already completed the accounting to get off the pinksheets and should be listed on the OTCBB soon.

4) Dr. Frudakis was responsible for a patent that sold for $54,000,000 to Smith Kline Beecham while he was at Corixa.

5) Corixa's stock has gone from 14 Cents a few years ago to 50 Dollars today.

6) According to the Barron's article, Dnaprint is in the late stages of forming strategic alliances with major companies.

7) DNAP is trading at 23.5 cents as of Friday's close !!!!!!!!!!!!!!!

 This is not from a registered financial advisory, please consult with a registered investment advisor before making an investment decision. This communication (print or electronic) reflects our opinions and does not necessarily reflect those of anyone else related to the firm and may be in conflict with the views or official views of the companies mentioned. Readers are advised that this publication (print or electronic) is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy. This communication is based on information available to the public. We are NOT a professional advisory service, broker, investment firm or agency. We are NOT a stock picking service. The securities profiled here are solely of our own opinion and it is not recommended that you buy, sell, or hold based on what you find here. Please continue to perform your own Due Diligence.  Any investment decisions you make should be your own predicated upon your own findings and judgments born from your own research. All images and logo's used to represent DNAPrint are registered trademarks of DNAPrint. Barrons is a registered trademark of Dow Jones & Co., Inc..
  

TEXT Version:
 
    Dnaprint (DNAP) is an emerging biotech company in this weeks Barrons.

1) CEO (Dr. Tony Frudakis) Lead scientist for Corixa starts his own company a 
   few months ago
    
2) Company is formed by a reverse merger of a pinksheet company

3) DNAP has already completed the accounting to get off the pinksheets and 
   should be listed on the OTCBB soon.

4) Dr. Frudakis was  responsible for a patent that sold for $54,000,000 to 
   Smith Kline Beecham while he was at Corixa.
 
5) Corixa's stock has gone from 14 Cents a few years ago to 50 Dollars today.
 
6) According to the Barron's article, Dnaprint is in the late stages of forming 
   strategic alliances with major companies.

7) Dnap is trading at 23.5 cents at Friday's close !!!!






_______________________________________________
Nettime-bold mailing list
Nettime-bold@nettime.org
http://www.nettime.org/cgi-bin/mailman/listinfo/nettime-bold